



With a team of world class biologists and chemists



Providing laboratory support for clinical trials (Phase I-IV)



Development of new therapeutics, vaccines and diagnostics



In a quality-assured environment

DIRECTOR DESCRIPTION AND RESERVED TO THE RESER 20210623_14006_D1 12 hell 6 etim STATS CD14+ 10623 14006 D1 12 hr-IL6 sti AT3 CD14+

The 360biolabs advantage

PK and PD in the same laboratory

Ability to develop client-specific assays not available elsewhere



Quality systems

Internationally recognized GLP, GCP, ISO/IEC 17025

ICH/FDA/EMA compliant assay validation and reporting



Expert, industry experienced team with a proven track record

We've been in our clients' shoes



Communication and flexibility

Responsive, rapid turnaround on quotations, data transfers and reports



"Every sample counts" mindset

Delivery of high-quality data, on-time, every time


Servicing diverse fields

Vaccines, therapeutics and diagnostics

- > Oncology
- > Immuno-therapeutics
- > Infectious diseasesVaccines, Antivirals
- > Thrombotic diseases
- > Neurological disorders
- > Respiratory diseases
- Inflammatory and autoimmune diseases
- > And many more...

Pharmacokinetic (PK)

from simple to complex - customised to your needs



Small molecules, peptides & small proteins

- Agilent & Sciex LC-MS/MS systems including
 - > Sciex 7500
 - > 6460 & 6465 triple quad, 6495 high sensitivity triple quad MS
 - 1290 Infinity II UPLC systems including temp controlled high capacity autosamplers
 - > 6546 LC/Q-TOF for metabolite analysis


Large molecule

- MSD (chemiluminescence)
- > ELISA (absorbance)

Pharmacodynamic (PD) from simple to complex - customised to your needs



- > Flow cytometry (T, B, NK,Tregs, DCs, RO, customised panels)
- › Biomarker profiling MSD, ELISA, Luminex, SIMOA
- > ELISA (therapeutic specific development)
- Anti-drug antibody (ADA)
 - Screening, confirmatory, titer
 - Nab cell-based assay development and testing
- Neutralisation
- → ELISPOT



Virology

- > Plaque reduction neutralization test (PRNT)
- Plaque assay (PA)
- Quantitative (TCID₅₀) and qualitative culture (flask)
- Quantitative and qualitative PCR
- Virus subtyping
- Hemagglutinin inhibition (HAI)
- Microneutralization
- Resistance characterization

Vaccine experience

SARS-CoV-2

- Microneutralisation
- Vaccine specific ELISAs
- qPCR
- Serology (IgA/IgG)
- ELISPOT
- Flow cytometry
- PBMC isolation

Seasonal Influenza

- HAI
- Microneutralisation
- ELISPOT
- Flow cytometry
- PBMC isolation

Respiratory Syncytial Virus

- Vaccine specific ELISA
- PBMC isolation

EV71

Plaque Reduction
 Neutralisation Test (PRNT)

Chikungunya

Plaque Reduction
 Neutralisation Test (PRNT)

Pertussis

· Vaccine specific ELISAs

Poxvirus

Microneutralisation

HSV-1

- ELISA
- Flow cytometry
- qPCR
- ADA
- Cytokines

Malaria

- ELISA
- ELISPOT

Peanut allergy

 Basophil Activation Test (BAT)

Adenovirus

Plaque Assay Microneutralisation

Measles/Rubella

Foci Assay

VZV

ELISA Flow Cytometry

Zika

Plaque Reduction
 Neutralisation Test (PRNT)



Pharmacodynamic (PD) diverse, specialised, customised



Molecular


- › Gene expression via WB
- > Quantitative and qualitative PCR
- Genotyping
- > SNP, WGS, NGS
- > SDS-PAGE gel
- Molecular RACE assays




- Laboratory manuals and site training
- Sample collection kits
- Clinical sample logistics
- Sample processing
- Isolation and cryopreservation PBMC
- > Plasma and serum aliquoting
- DNA/RNA extraction, quantification, concentration, purity
- Biobanking 24/7 monitoring

CLS services are only available for clinical studies where 360biolabs is supporting downstream analysis of samples

Our Clients by type



Our Clients by Country





Melbourne, Australia

- Leading biomedical R&D centre
- Australia's fastest growing city
- > Within Burnet Institute
- > Phase I unit
- Within a large hospital and translational medical precinct



Brisbane, Australia

- Translational Research Institute (TRI)
- Leading innovative medical research, development and translation facility
- Australian-first initiative of "bench to bedside" medical research precinct
- Situated in the Princess Alexandra Hospital precinct
- Two specialised Clinical Trial units
- Close proximity to Phase 1 unit

ONE TEAM. ONE MISSION.





The Australian advantage Speed. Quality. Cost.

- Fast regulatory environment
 - > IND not required
- Internationally recognised quality systems
- R&D Tax Incentive (43.5%)
 - All activities conducted at 360biolabs can be claimed by R&D TI



William Hunter

Sr. Director of Business Development bd@360biolabs.com +61 (0) 436 369374

One team. One mission. ENABLING FUTURE MEDICINES